Ethyl eicosapentaenoic acid/rosuvastatin

Drug Profile

Ethyl eicosapentaenoic acid/rosuvastatin

Alternative Names: AMR-102; Ethyl eicosapentaenoic acid/rosuvastatin - Amarin; Icosapent ethyl/rosuvastatin - Amarin; Vascepa/rosuvastatin - Amarin

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amarin Corporation
  • Class Antihyperlipidaemics; Eicosanoids; Fluorobenzenes; Omega 3 fatty acids; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action HMG-CoA reductase inhibitors; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Hyperlipidaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hyperlipidaemia in USA (PO)
  • 21 Jun 2013 Safety and pharmacokinetics data from a phase I trial in healthy volunteers released by Amarin
  • 17 Dec 2012 Phase-I clinical trials in Hyperlipidaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top